You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
透視港股通丨贛鋒鋰業遭淨賣出近2億

北水總結

4月11日港股市場,北水成交淨買入0.68億,其中港股通(滬)成交淨買入1.86億港元,港股通(深)成交淨賣出1.18億港元。

北水淨買入最多的個股是美團-W(03690)、中海油(00883)、安踏體育(02020)。北水淨賣出最多的個股是李寧(02331)、華潤啤酒(00291)、騰訊(00700)。

數據來源:盈立智投APP

十大成交活躍股

數據來源:港交所

個股點評

美團-W(03690)獲淨買入3.72億港元。消息面上,中金髮表研究報告指,美團外賣、到店及旅遊等主要業務面對短期壓力,但公司新業務追求高質量增長。該行指,公司預計新業務收入增長將保持穩定,由於運營效率和競爭格局的優化,虧損將收窄。中金維持對其今明兩年預測,評級“跑贏行業”保持不變,目標價265港元。

中海油(00883)獲淨買入3.08億港元。消息面上,中國海洋石油公告,於2022年4月6日和4月7日完成向詢價對象進行的初步詢價後,公司將按發行價格每股人民幣10.80元發行26億股人民幣股份(行使超額配售選擇權前)至29.9億股人民幣股份(若全額行使超額配售選擇權)。

體育用品股今日現分化,安踏體育(02020)獲淨買入2.16億港元,而李寧(02331)再遭淨賣出2.47億港元。消息面上,興業證券發佈研報稱,服裝零售消費端受疫情衝擊較大,線上物流和線下客流都受到了不同程度的衝擊,特別是主力門店在1/2線城市的品牌,3月和4月受波及程度較大,近期低迷的股價也反應了較低的預期。

開拓藥業-B(09939)獲淨買入6310萬港元。消息面上,開拓藥業此前發佈公告,公佈其新冠口服藥普克魯胺治療新冠輕中症的全球多中心三期臨牀(NCT04870606)關鍵數據結果。數據顯示,普克魯胺有效降低新冠患者(主要受Delta和Omicron變異株感染)的住院/死亡率,特別是對於服藥超過7天的全部患者,以及伴有高風險因素的中高年齡新冠患者達到100%保護率,具有統計學顯著性。同時,普克魯胺可以顯著降低新冠病毒載量,改善相關新冠症狀。招銀國際發佈研究報告稱,維持開拓藥業-B“買入”評級,目標價由34.37港元上調至48.78港元,看好其新冠口服藥普克魯胺治療潛力。

舜宇光學(02382)遭淨賣出1.59億港元。消息面上,大摩發佈研究報告稱,予舜宇光學科技“增持”評級,首季付運如預期疲弱,可能減弱投資者對其2022年的期望,而目前疫情或成爲公司4月份的不利因素,但其後的潛在復甦或有助於對該股估值重評,目標價190港元。

贛鋒鋰業(01772)遭淨賣出1.88億港元。消息面上,4月9日特斯拉CEO馬斯克在社交媒體上表示,特斯拉可能會直接大規模地涉足鋰礦開採和精煉業務,因該製造電池關鍵部件的金屬成本已經變得非常高。分析人士稱,特斯拉進軍鋰礦行業或影響當前行業競爭格局,此前市場保有產能或不斷飽和,若其他電車企業效仿特斯拉完善全產業佈局,鋰礦行業競爭或將更加激烈。

此外,中國神華(01088)、中國移動(00941)、小米集團-W(01810)分別獲淨買入1.41億、9356萬、4821萬港元。而華潤啤酒(00291)、騰訊(00700)、建設銀行(00939)分別遭淨賣出2.3億、2.22億、1.65億港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account